Sayer Ji
Founder of GreenMedInfo.com

Sign up for our Free Newsletter

A Community of 200,000+ Subscribers benefit from our latest research and news.

Abstract Title:

Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial.

Abstract Source:

J Clin Pharm Ther. 2010 Oct ;35(5):581-8. PMID: 20831681

Abstract Author(s):

S Akhondzadeh, M Shafiee Sabet, M H Harirchian, M Togha, H Cheraghmakani, S Razeghi, S Sh Hejazi, M H Yousefi, R Alimardani, A Jamshidi, F Zare, A Moradi

Article Affiliation:

Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran Institute of Medicinal Plants (ACECR), Department of Neurology, Tehran, Iran. s.akhond@neda.net

Abstract:

UNLABELLED: WHAT IS KNOWN: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloidβ in the human brain and may therefore be useful in Alzheimer's disease (AD).

OBJECTIVE: The goal of this study was to assess the efficacy of saffron in the treatment of mild to moderate AD.

METHODS: Forty-six patients with probable AD were screened for a 16-week, double-blind study of parallel groups of patients with mild to moderate AD. The psychometric measures, which included AD assessment scale-cognitive subscale (ADAS-cog), and clinical dementia rating scale-sums of boxes, were performed to monitor the global cognitive and clinical profiles of the patients. Patients were randomly assigned to receive capsule saffron 30 mg/day (15 mg twice per day) (Group A) or capsule placebo (two capsules per day) for a 16-week study.

RESULTS: After 16 weeks, saffron produced a significantly better outcome on cognitive function than placebo (ADAS-cog: F=4·12, d.f.=1, P=0·04; CDR: F=4·12, d.f.=1, P=0·04). There were no significant differences in the two groups in terms of observed adverse events. WHAT IS NEW AND CONCLUSION: This double-blind, placebo-controlled study suggests that at least in the short-term, saffron is both safe and effective inmild to moderate AD. Larger confirmatory randomized controlled trials are called for.

Study Type : Human Study
Additional Links
Additional Keywords : Phytotherapy : CK(1216) : AC(221)

Print Options


Key Research Topics

Popular Threads

Sayer Ji
Founder of GreenMedInfo.com

Sign up for our Free Newsletter

A Community of 200,000+ Subscribers benefit from our latest research and news.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2017 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.